EUROEYES INTERNATIONAL EYE CLINIC LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.95 HKD | +3.12% |
|
+5.54% | -4.99% |
| Apr. 26 | EuroEyes International to Buy Back Up to 3% Shares | MT |
| Apr. 24 | EuroEyes International Logs 6% Growth in Q1 Eye Surgeries | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- With a P/E ratio at 10.31 for the current year and 8.25 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.99% | 211M | - | ||
| -21.25% | 2.91B | - | ||
| -20.94% | 2.67B | C+ | ||
| -60.16% | 2.06B | C- | ||
| -25.10% | 323M | - | ||
| -47.38% | 172M | - | - | |
| -27.37% | 123M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 1846 Stock
- Ratings EuroEyes International Eye Clinic Limited
